Please activate JavaScript!
Please install Adobe Flash Player, click here for download

ISCB2014_abstract_book

ISCB 2014 Vienna, Austria • Abstracts - Poster Presentations 101Monday, 25th August 2014 • 15:30-16:00 Monday25thAugustTuesday26thAugustThursday28thAugustAuthorIndexPostersWednesday27thAugustSunday24thAugust P1.3.123 Choice-based conjoint (CBC) analysis to evaluate patient’s perception regarding their erythropoiesis stimulating agent (ESA) treatment in chronic kidney disease (CKD) D Pau1 , G Choukroun2 , O Moranne3 , C Vigneau4 , C Isnard-Bagnis5 , N Belamri1 , S Pibre1 1 Roche, Boulogne-Billancourt, France, 2 CHU Amiens, Amiens, France, 3 Hôpital Pasteur, Nice, France, 4 Hôpital Pontchaillou, Rennes, France, 5 AP-HP Pitié-Salpêtrière, Paris, France   Background: In recent years, a growing interest emerged for patients’ perception of treatment they received. In CKD patients receiving ESA, few data exist regarding their preference/satisfaction with medications. Objectives: CBC analysis is a major market research methodology for studying how people value the characteristics of products/services. The objective of CBC is to determine what combination of a limited number of characteristics is most influential on respondent choice. This technique has been implemented in a clinical study to describe patient’s perception and preference regarding their ESA treatment. Methods: Percepolis is a 6-month multicenter prospective non-interven- tional study. The primary endpoint was the relative importance according by CKD patient to characteristics of their ESA treatments. CBC question- naires were developed using the following multiple components: • 7 ESA characteristics, • 2 or 3 levels/characteristics, • each possible answer includes 1 level for 2 characteristics, • 2 choices/question, • 7 questions/questionnaire. Twenty questionnaires have been generated in order to mix all possible treatment characteristics/levels. Patients only had to answer one ques- tionnaire and randomization was used to obtain equal number of respon- dents for each questionnaire. Conclusions: CBC analysis results were made available and interpreted. CBC analysis can be considered as a useful technique to evaluate patient’s perception and can be implemented in outcomes research when selective data collection is pre-planned. P1.3.136 Fast track assessment of generics in Portugal M Ribeirinho1 1 INFARMED - National Authority on Medicines & Health Products, Lisboa, Portugal   Background: In 2013, Portugal implemented the fast track assess- ment of generics in terms of reimbursement and price decision, making mandatory to evaluate generics in 4 days while in the past the deadline was 75 days. This managed to speed up the entrance of generics in the Portuguese market reflecting an increase in their use potentiating several health gains. Aim: To establish a relation between the fast track of Health Technology Assessment with the increase availability and use of generics. To deter- mine the impact of this intervention in the National Health Service by modelling all events and agents. Methods Data was collected from gener- ics evaluated since 2012 combining utilization data from prescriptions in NHS ambulatory care. Statistical methods were performed such as ANOVA procedures and Regression Intervention Models. Results: With the fast track, generics are now fully assessed in 4 days while in 2012 the average conclusion time was 84 days. As a result, they now en- ter the reference price system much faster allowing more affordable pric- es. This procedure had an impact in the use of generics, increasing 18%, whose market share raised 5% now reaching 40%. Statistical relation was significant at p<0.07.Regression model revealed that savings achieved for both Patients and NHS can be address to the fast track (p<0,08). Conclusions: One year after the implementation of this new assessment scheme, generics increase and expenditure savings due to it were statis- tical significant. Time and resources saved in this evaluation can now be used to assess innovative medicines.

Pages Overview